Citigroup Inc Axogen, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Axogen, Inc. stock. As of the latest transaction made, Citigroup Inc holds 30,751 shares of AXGN stock, worth $551,057. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,751

Previous 9,231 233.13%

Holding current value

$551,057

Previous $66,000 553.03%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$7.52 - $14.69 $161,830 - $316,128	21,520 Added 233.13%	30,751 $431,000
Q2 2024 Aug 12, 2024	BUY	$5.67 - $8.06 $13,460 - $19,134	2,374 Added 34.62%	9,231 $66,000
Q1 2024 May 10, 2024	BUY	$6.63 - $10.69 $6,437 - $10,379	971 Added 16.5%	6,857 $55,000
Q4 2023 Feb 09, 2024	BUY	$3.61 - $7.76 $20,901 - $44,930	5,790 Added 6031.25%	5,886 $40,000
Q3 2023 Nov 09, 2023	SELL	$4.68 - $9.26 $61,003 - $120,704	-13,035 Reduced 99.27%	96 $0
Q2 2023 Aug 10, 2023	BUY	$8.5 - $10.38 $103,037 - $125,826	12,122 Added 1201.39%	13,131 $119,000
Q1 2023 May 11, 2023	SELL	$7.53 - $10.95 $1,987 - $2,890	-264 Reduced 20.74%	1,009 $9,000
Q4 2022 Feb 09, 2023	BUY	$9.44 - $13.09 $4,672 - $6,479	495 Added 63.62%	1,273 $12,000
Q3 2022 Nov 10, 2022	SELL	$8.14 - $12.25 $16,141 - $24,291	-1,983 Reduced 71.82%	778 $9,000
Q2 2022 Aug 10, 2022	BUY	$6.99 - $10.0 $789 - $1,130	113 Added 4.27%	2,761 $23,000
Q1 2022 May 12, 2022	SELL	$7.26 - $10.7 $58,283 - $85,899	-8,028 Reduced 75.2%	2,648 $21,000
Q4 2021 Feb 10, 2022	BUY	$8.8 - $16.0 $50,001 - $90,912	5,682 Added 113.78%	10,676 $100,000
Q3 2021 Nov 10, 2021	BUY	$15.23 - $21.72 $76,058 - $108,469	4,994 New	4,994 $79,000

Others Institutions Holding AXGN

# of Institutions

166

Shares Held

36.2M

Call Options Held

230K

Put Options Held

400

View Full List

About Axogen, Inc.

Ticker AXGN
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 42,283,700
Market Cap $758M
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...

More about AXGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account